Analyst sentiment remains mixed despite the upgrade. MarketBeat data show a consensus "Moderate Buy" rating from ten covering firms, with eight buy ratings, one strong buy, and one sell. The average 12-month price target across those firms sits at $26.13, well below H.C. Wainwright's new $55 mark. Mizuho lifted its target to $30 from $24 on Monday, while Guggenheim holds a $40 target and Citigroup a $26 target. Weiss Ratings maintains a "sell (d-)" rating and Wall Street Zen rates the stock a sell.
Insider activity shows Gina Mazzariello sold 15,000 shares at an average price of $18.32 on July 9, reducing her direct holdings to 194,090 shares. Insiders own approximately 10.9% of outstanding stock.
The $55 target implies substantial upside from current levels, but the gap between that figure and the broader consensus underscores the uncertainty around regulatory approval, commercial execution, and the durability of the trial benefit. Investors will now watch for the NDA submission timeline, FDA review milestones, and whether other analysts revise their models to reflect a potential 2027 launch.
What to Watch
Can Amylyx translate a single successful Phase 3 study into a sustainable commercial franchise after its previous ALS setback?
Sources: Source 1 · Source 2 · Source 3 · Source 4 · Source 5 · Source 6
